Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey

Heather Lau, Nadia Belmatoug, Patrick Deegan, Ozlem Goker-Alpan, Ida Vanessa D. Schwartz, Suma Shankar, Zoya Panahloo, Ari Zimran

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Gaucher disease (GD) may worsen during pregnancy, leading to the discussion of continuing treatment during pregnancy. We examined fetal outcomes of pregnancies reported in the Gaucher Outcome Survey, an international GD-specific registry established in 2010. A total of 453 pregnancies were reported. Most pregnancies (336/453, 74.2%) were in women who did not receive GD-specific treatment during pregnancy, while enzyme replacement therapy (ERT) was received during 117/453 (25.8%) pregnancies. No pregnancies exposed to substrate reduction therapy were reported. The percentage of normal outcomes (live birth delivered at term with no congenital abnormalities) was similar in untreated and treated pregnancies (92.9% vs. 91.4%). The percentage of spontaneous abortions in untreated pregnancies was 3.6% (95% CI, 1.9%– 6.2%) compared with 6.9% (95% CI, 3.0%–13.1%) in treated pregnancies (p = 0.1866). In women who received velaglucerase alfa < 1 month prior to conception and/or during pregnancy, 34/36 (94.4%) pregnancies had normal outcomes and 2 (5.6%) ended in spontaneous abortion. Normal outcomes were observed in the 20 pregnancies with velaglucerase alfa exposure starting < 1 month prior to conception and continuing through all trimesters. These observations, in addition to information in the literature, suggest that continuation of ERT during pregnancy may be appropriate for GD patients.

Original languageEnglish (US)
Pages (from-to)226-231
Number of pages6
JournalBlood Cells, Molecules, and Diseases
Volume68
DOIs
StatePublished - Feb 1 2018
Externally publishedYes

Fingerprint

Gaucher Disease
Pregnancy Outcome
Pregnancy
Enzyme Replacement Therapy
Spontaneous Abortion
Surveys and Questionnaires
Live Birth

Keywords

  • Enzyme replacement therapy
  • Gaucher disease
  • Pregnancy
  • Velaglucerase alfa

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Hematology
  • Cell Biology

Cite this

Reported outcomes of 453 pregnancies in patients with Gaucher disease : An analysis from the Gaucher outcome survey. / Lau, Heather; Belmatoug, Nadia; Deegan, Patrick; Goker-Alpan, Ozlem; Schwartz, Ida Vanessa D.; Shankar, Suma; Panahloo, Zoya; Zimran, Ari.

In: Blood Cells, Molecules, and Diseases, Vol. 68, 01.02.2018, p. 226-231.

Research output: Contribution to journalArticle

Lau, Heather ; Belmatoug, Nadia ; Deegan, Patrick ; Goker-Alpan, Ozlem ; Schwartz, Ida Vanessa D. ; Shankar, Suma ; Panahloo, Zoya ; Zimran, Ari. / Reported outcomes of 453 pregnancies in patients with Gaucher disease : An analysis from the Gaucher outcome survey. In: Blood Cells, Molecules, and Diseases. 2018 ; Vol. 68. pp. 226-231.
@article{008220e8694e4177a159719cb89630b7,
title = "Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey",
abstract = "Gaucher disease (GD) may worsen during pregnancy, leading to the discussion of continuing treatment during pregnancy. We examined fetal outcomes of pregnancies reported in the Gaucher Outcome Survey, an international GD-specific registry established in 2010. A total of 453 pregnancies were reported. Most pregnancies (336/453, 74.2{\%}) were in women who did not receive GD-specific treatment during pregnancy, while enzyme replacement therapy (ERT) was received during 117/453 (25.8{\%}) pregnancies. No pregnancies exposed to substrate reduction therapy were reported. The percentage of normal outcomes (live birth delivered at term with no congenital abnormalities) was similar in untreated and treated pregnancies (92.9{\%} vs. 91.4{\%}). The percentage of spontaneous abortions in untreated pregnancies was 3.6{\%} (95{\%} CI, 1.9{\%}– 6.2{\%}) compared with 6.9{\%} (95{\%} CI, 3.0{\%}–13.1{\%}) in treated pregnancies (p = 0.1866). In women who received velaglucerase alfa < 1 month prior to conception and/or during pregnancy, 34/36 (94.4{\%}) pregnancies had normal outcomes and 2 (5.6{\%}) ended in spontaneous abortion. Normal outcomes were observed in the 20 pregnancies with velaglucerase alfa exposure starting < 1 month prior to conception and continuing through all trimesters. These observations, in addition to information in the literature, suggest that continuation of ERT during pregnancy may be appropriate for GD patients.",
keywords = "Enzyme replacement therapy, Gaucher disease, Pregnancy, Velaglucerase alfa",
author = "Heather Lau and Nadia Belmatoug and Patrick Deegan and Ozlem Goker-Alpan and Schwartz, {Ida Vanessa D.} and Suma Shankar and Zoya Panahloo and Ari Zimran",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.bcmd.2016.10.003",
language = "English (US)",
volume = "68",
pages = "226--231",
journal = "Blood Cells, Molecules, and Diseases",
issn = "1079-9796",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Reported outcomes of 453 pregnancies in patients with Gaucher disease

T2 - An analysis from the Gaucher outcome survey

AU - Lau, Heather

AU - Belmatoug, Nadia

AU - Deegan, Patrick

AU - Goker-Alpan, Ozlem

AU - Schwartz, Ida Vanessa D.

AU - Shankar, Suma

AU - Panahloo, Zoya

AU - Zimran, Ari

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Gaucher disease (GD) may worsen during pregnancy, leading to the discussion of continuing treatment during pregnancy. We examined fetal outcomes of pregnancies reported in the Gaucher Outcome Survey, an international GD-specific registry established in 2010. A total of 453 pregnancies were reported. Most pregnancies (336/453, 74.2%) were in women who did not receive GD-specific treatment during pregnancy, while enzyme replacement therapy (ERT) was received during 117/453 (25.8%) pregnancies. No pregnancies exposed to substrate reduction therapy were reported. The percentage of normal outcomes (live birth delivered at term with no congenital abnormalities) was similar in untreated and treated pregnancies (92.9% vs. 91.4%). The percentage of spontaneous abortions in untreated pregnancies was 3.6% (95% CI, 1.9%– 6.2%) compared with 6.9% (95% CI, 3.0%–13.1%) in treated pregnancies (p = 0.1866). In women who received velaglucerase alfa < 1 month prior to conception and/or during pregnancy, 34/36 (94.4%) pregnancies had normal outcomes and 2 (5.6%) ended in spontaneous abortion. Normal outcomes were observed in the 20 pregnancies with velaglucerase alfa exposure starting < 1 month prior to conception and continuing through all trimesters. These observations, in addition to information in the literature, suggest that continuation of ERT during pregnancy may be appropriate for GD patients.

AB - Gaucher disease (GD) may worsen during pregnancy, leading to the discussion of continuing treatment during pregnancy. We examined fetal outcomes of pregnancies reported in the Gaucher Outcome Survey, an international GD-specific registry established in 2010. A total of 453 pregnancies were reported. Most pregnancies (336/453, 74.2%) were in women who did not receive GD-specific treatment during pregnancy, while enzyme replacement therapy (ERT) was received during 117/453 (25.8%) pregnancies. No pregnancies exposed to substrate reduction therapy were reported. The percentage of normal outcomes (live birth delivered at term with no congenital abnormalities) was similar in untreated and treated pregnancies (92.9% vs. 91.4%). The percentage of spontaneous abortions in untreated pregnancies was 3.6% (95% CI, 1.9%– 6.2%) compared with 6.9% (95% CI, 3.0%–13.1%) in treated pregnancies (p = 0.1866). In women who received velaglucerase alfa < 1 month prior to conception and/or during pregnancy, 34/36 (94.4%) pregnancies had normal outcomes and 2 (5.6%) ended in spontaneous abortion. Normal outcomes were observed in the 20 pregnancies with velaglucerase alfa exposure starting < 1 month prior to conception and continuing through all trimesters. These observations, in addition to information in the literature, suggest that continuation of ERT during pregnancy may be appropriate for GD patients.

KW - Enzyme replacement therapy

KW - Gaucher disease

KW - Pregnancy

KW - Velaglucerase alfa

UR - http://www.scopus.com/inward/record.url?scp=85006488880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006488880&partnerID=8YFLogxK

U2 - 10.1016/j.bcmd.2016.10.003

DO - 10.1016/j.bcmd.2016.10.003

M3 - Article

C2 - 27839985

AN - SCOPUS:85006488880

VL - 68

SP - 226

EP - 231

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

SN - 1079-9796

ER -